GLG News by Ritalin Prescribers

My personal prediction is that this product will NOT be on the market in 3-5 years.  My clinical experience never approached that which the research would suggest.  I suspect that the "research" that was done on this product is frought with company incentives.

As a partner @ a VC fund I  see this trend impacting how potential portfolio companies are evaluated.  Companies that will have a future acquisition, as an liquidity event, will have a higher probability of being funded.  Investment decisons are also being influenced by the potential...

This is a very significant event for Ceregene.  Previous studies, with drug treatment, on treatment for parkinsons have shown that the placebo effect only lasts for three months.  The symptoms of Parkinson's  increase 5-10% per year( as part of the natural progression of the disorder). ...

Lilly is currently leader in Psychiatry with 4 active medications with great marketing for Psychiatry and Primary care physician. New compound that has a unique mechanism on Metabotropic Glutamate 2/3 Receptors, can work on Schizophrenia and other Psychiatric diagnosis. This is great opportunity...

I have long been concerned about this issue - not only for Hep B, but moreover for Varicella, and measles, etc.  It is my prediction that, before the end of my medical career, immunizations will take a greater part in the Family Medicine/Internal Medicine practices, and people will need to receive...

Intuniv is likely to be well-received by clinicians as a new medication for ADHD.  Although guanfacine, as a non-stimulant, has historically not been considered as effective as stimulants for the treatment of ADHD, it will likely have a stronger launch than Strattera because of several non-clinical...

Review of Shire's clinical data and promotional materials to physicians suggests Vyvanse may have limited advantages over Adderall XR.  This article briefly addresses comparative issues (Adderall XR vs. Vyvanse) with respect to adverse events, pharmacokinetics, duration of clinical benefit, and...

Yet another antihistamine in a saturated market with less expensive alternatives. Antihistamines are not the drug of choice for significant allergic rhinitis

Promissing but need for more clinical data is obvious

We need to separate the concepts of Checkups from "Shots." This delivery system adds credence to this  - it is impossible to talk to a parent, whose child is screaming after a vaccine, or who is stressed because the parent has "threatened" the child with a "shot."  (grounds for dismissal from...